LONG-TERM SURVIVAL AND COMPLICATIONS IN PATIENTS WITH MECHANICAL AORTIC VALVES WITHOUT ANTICOAGULATION - A FOLLOW-UP-STUDY FROM 1 TO 15 YEARS

被引：11

作者：

ANDERSEN, PV ^{[1
]}

ALSTRUP, P ^{[1
]}

机构：

[1] ODENSE UNIV HOSP,DEPT CARDIOTHORAC SURG,DK-5000 ODENSE,DENMARK

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1992年 / 6卷 / 02期

关键词：

AORTIC VALVE; EMBOLISM; ANTICOAGULANTS;

D O I：

10.1016/1010-7940(92)90076-A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In aortic valve replacement most centres prefer to use a mechanical valve for younger patients without special bleeding risks and treat the patient with lifelong anticoagulation. However, a few patients do not receive anticoagulation at all or have this withdrawn after some time. We examined the prognosis of 43 patients, 37 men and 6 women (mean age 52 years), who were treated with anticoagulation for approximately only 1 year (mean 13 months; range 4-35 months) after isolated aortic valve replacement with a mechanical valve. The mean follow-up period was 7 years and 3 months (1.5 months to 15 years and 10 months). After 5 and 10 years, 70% and 59%, respectively, were free of thromboembolic events, 65% and 55%, respectively, were free of valve-related events, and 87% and 83%, respectively, had survived. These figures correspond to linearized rates of thromboembolic events of 5.2%/pt-yr, valve-related events of 6.2%/pt-yr and death of 2.9%/pt-yr. We conclude that the best postoperative treatment in isolated aortic valve replacement with a mechanical valve is lifelong anticoagulation.

引用

页码：62 / 65

页数：4

共 15 条

[1]

Beaudet E.M., Oca C.C., Roques X.F., Laborde M.N., Hafez A.S., Coilot M.A., Gnidoni I.M., A 5 Vi year experience with the St. Jude medical cardiac valve prosthesis. Early and late results of 737 valve replacements in 671 patients, J Thorac Cardiovasc Surg, 90, pp. 137-144, (1985)

[2]

Cheung D., Flemma R.J., Mullen D.C., Lepley D., Anderson A.J., Weirauch E., Ten year follow-up in aortic valve replacement using the Bjôrk-Shiley prosthesis, Ann Thorac Surg, 32, pp. 138-154, (1981)

[3]

Cutler S.J., Ederer F., Maximum utilization of the life table method in analyzing survival, J Chronic Dis, 8, pp. 699-712, (1958)

[4]

Edmunds H.L., Clark R.E., Cohn L.H., Miller D.C., Weisel R.D., Guidelines for reporting morbidity and mortality after cardiac valvular operations, Ann Thorac Sure, 46, pp. 257-259, (1988)

[5]

Kinsley R.H., Antunes M.J., Colsen P.R., St. Jude Medical valve replacement. An evaluation of valve performance, J Thorac Cardiovasc Surg, 92, pp. 349-360, (1986)

[6]

Larsen G.L., Alexander J.A., Stanford W., Thromboembolic phenomena in patients with prosthetic aortic valves, who did not receive anticoagulants, Ann Thorac Surg, 23, pp. 323-326, (1977)

[7]

Levang O.W., Aortic valve replacement. A randomized study comparing the Bjork-Shiley and Lillehei-Kaster disc valve. Long term results, Scand J Thorac Cardiovasc Surg, 15, 1, pp. 39-48, (1981)

[8]

Limet R., Lepage G., Grondin C.M., Thromboembolic complications with the cloth covered Starr Edwards aortic prosthesis in patients not receiving anticoagulants, Ann Thorac Surg, 23, pp. 529-533, (1977)

[9]

Lindblom D., Long-term clinical results after aortic valve replacement with the Bjôrk-Shiley prosthesis, J Thorac Cardiovasc Surg, 95, pp. 658-667, (1988)

[10]

Lund O., Vaeth M., Prediction of late results following valve replacement in aortic valve stenosis. Seventeen years of follow-up examined with the Cox regression analysis, Thorac Cardiovasc Surgeon, 35, pp. 295-303, (1987)

← 1 2 →